BML Capital Management LLC Purchases New Position in Outset Medical, Inc. $OM

BML Capital Management LLC purchased a new stake in Outset Medical, Inc. (NASDAQ:OM) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 543,180 shares of the company’s stock, valued at approximately $2,015,000. Outset Medical makes up approximately 1.7% of BML Capital Management LLC’s investment portfolio, making the stock its 9th biggest holding.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Assenagon Asset Management S.A. boosted its holdings in Outset Medical by 34.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 508,414 shares of the company’s stock valued at $1,886,000 after purchasing an additional 131,381 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Outset Medical by 1,276.1% in the third quarter. JPMorgan Chase & Co. now owns 116,306 shares of the company’s stock valued at $1,642,000 after purchasing an additional 107,854 shares in the last quarter. Alyeska Investment Group L.P. boosted its holdings in Outset Medical by 10.2% in the third quarter. Alyeska Investment Group L.P. now owns 1,614,582 shares of the company’s stock valued at $22,798,000 after purchasing an additional 150,000 shares in the last quarter. Millennium Management LLC boosted its holdings in Outset Medical by 165.8% in the third quarter. Millennium Management LLC now owns 421,409 shares of the company’s stock valued at $5,950,000 after purchasing an additional 262,874 shares in the last quarter. Finally, Citadel Advisors LLC boosted its holdings in Outset Medical by 372.8% in the third quarter. Citadel Advisors LLC now owns 96,084 shares of the company’s stock valued at $1,357,000 after purchasing an additional 75,762 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Wall Street Zen downgraded Outset Medical from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Stifel Nicolaus decreased their price objective on Outset Medical from $14.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, January 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of Outset Medical in a report on Friday, March 27th. Finally, BTIG Research decreased their price objective on Outset Medical from $17.00 to $15.00 and set a “buy” rating for the company in a report on Thursday, February 12th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Outset Medical Price Performance

OM stock opened at $4.77 on Wednesday. The company has a market capitalization of $88.39 million, a P/E ratio of -0.70 and a beta of 1.92. Outset Medical, Inc. has a twelve month low of $3.00 and a twelve month high of $21.98. The business has a 50 day simple moving average of $3.84 and a 200-day simple moving average of $5.37. The company has a current ratio of 6.67, a quick ratio of 5.40 and a debt-to-equity ratio of 0.76.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long?term care facilities and emergency response scenarios.